Viewing data from:

GUANFACINE HYDROCHLORIDE

ANDA

GUANFACINE HYDROCHLORIDE | A219033 | UNICHEM LABORATORIES LTD

4 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: INTUNIV(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 4 NDCs

Highest NADAC/Unit

$0.1783

per ea

Lowest NADAC/Unit

$0.1325

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
29300046301GUANFACINE HCL ER 4 MG TABLET	$0.1783	EA	Generic	—	2026-08-19
29300046201GUANFACINE HCL ER 3 MG TABLET	$0.1660	EA	Generic	—	2026-08-19
29300046101GUANFACINE HCL ER 2 MG TABLET	$0.1573	EA	Generic	—	2026-08-19
29300046001GUANFACINE HCL ER 1 MG TABLET	$0.1325	EA	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain8 active DMFs1 inactive

8 active API suppliers hold Drug Master Files for this ingredient.

MEDICHEM SAGUANFACINE HYDROCHLORIDE

DMF 85901990

QUIMICA SINTETICA SAGUANFACINE HYDROCHLORIDE

DMF 86611990

JUBILANT PHARMOVA LTDGUANFACINE HYDROCHLORIDE USP

DMF 280492014

PROCOS SPAGUANFACINE HYDROCHLORIDE

DMF 283122014

TORRENT PHARMACEUTICALS LTDGUANFACINE HYDROCHLORIDE USP

DMF 284432014

UNICHEM LABORATORIES LTDGUANFACINE HYDROCHLORIDE USP

DMF 346532020

PHARMABLOCK PHARMACEUTICALS (ZHEJIANG) CO LTDGUANFACINE HYDROCHLORIDE, NON-STERILE, BULK DRUG SUBSTANCE

DMF 364312021

ZHEJIANG GUOBANG PHARMACEUTICAL CO LTDGUANFACINE HYDROCHLORIDE

DMF 394042024

SANDOZ PHARMACEUTICALS CORP DIV SANDOZ INCInactiveGUANFACINE HYDROCHLORIDE

DMF 49851983

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (4)

Sort:

#001 — EQ 1MG BASE

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Nov 19, 2024

No patent or exclusivity listings for this strength.

#002 — EQ 2MG BASE

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Nov 19, 2024

#003 — EQ 3MG BASE

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Nov 19, 2024

#004 — EQ 4MG BASE

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Nov 19, 2024